Show simple item record

The pharmacokinetics of penicillamine in a female mongrel dog

dc.contributor.authorBergstrom, Richard F.en_US
dc.contributor.authorKay, Donald R.en_US
dc.contributor.authorWagner, John G.en_US
dc.date.accessioned2006-09-11T15:38:57Z
dc.date.available2006-09-11T15:38:57Z
dc.date.issued1981-10en_US
dc.identifier.citationBergstrom, Richard F.; Kay, Donald R.; Wagner, John G.; (1981). "The pharmacokinetics of penicillamine in a female mongrel dog." Journal of Pharmacokinetics and Biopharmaceutics 9(5): 603-621. <http://hdl.handle.net/2027.42/45080>en_US
dc.identifier.issn1573-8744en_US
dc.identifier.issn0090-466Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45080
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7334461&dopt=citationen_US
dc.description.abstractThe pharmacokinetic parameters of D-penicillamine were investigated by administering four intravenous bolus doses, four oral doses, and six constant rate intravenous infusions to a female mongrel dog at dosages comparable to 250, 500, 750, and 1000 mg in man. The pharmacokinetics of D-penicillamine demonstrated nonlinearity in the dog. There was more than proportional increase in the area under the whole blood concentration curve for an increase in the bolus intravenous dose. The steady state whole blood, plasma, and packed cell levels of penicillamine were increased more than proportionately for an increase in the intravenous infusion rate. Total body clearance of penicillamine was decreased by increasing the dose or the infusion rate of penicillamine. Correspondingly, the estimated half-life of unchanged penicillamine in the whole blood was decreased for increased intravenous bolus doses. The renal clearance of penicillamine was nonlinear, decreasing with time during the bolus experiments and increasing at higher infusion rates. The nonrenal clearance was decreased at higher infusion rates, suggesting that a saturable nonrenal elimination process exists for penicillamine in the dog. The nonlinearities that were observed in the dog, if also present in man, may be responsible in part for the dose related side effects reported clinically for penicillamine .en_US
dc.format.extent973954 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Mediaen_US
dc.subject.otherD-penicillamine Whole Blood and Plasma Concentrationsen_US
dc.subject.otherIv Bolus, Infusion, and Oral Administration of Penicil-lamineen_US
dc.subject.otherBiomedical Engineeringen_US
dc.subject.otherVeterinary Medicineen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherPharmacyen_US
dc.subject.otherBiochemistry, Generalen_US
dc.subject.otherD-penicillamine Pharmacokineticsen_US
dc.subject.otherRheumatoid Arthritisen_US
dc.subject.otherBioavailability of Penicillamineen_US
dc.subject.otherFemale Mongrel Dogen_US
dc.titleThe pharmacokinetics of penicillamine in a female mongrel dogen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumRackham Arthritis Research Unit and Upjohn Center for Clinical Pharmacology, The University of Michigan, 48109, Ann Arbor, Michigan; Division of Immunology and Rheumatology, Department of Medicine, University of Missouri, Columbia, Missourien_US
dc.contributor.affiliationumCollege of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan, 48109, Ann Arbor, Michigan; Lilly Research Laboratories, Lilly Laboratory for Clinical Research, Wishard Memorial Hospital, 46202, Indianapolis, Indianaen_US
dc.contributor.affiliationumCollege of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan, 48109, Ann Arbor, Michiganen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid7334461en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45080/1/10928_2005_Article_BF01061028.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF01061028en_US
dc.identifier.sourceJournal of Pharmacokinetics and Biopharmaceuticsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.